![Jae-Seung Kim](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jae-Seung Kim
Directeur/Bestuurslid bij QURIENT CO., LTD.
Vermogen: 546 524 $ op 31-05-2024
Profiel
Jae-Seung Kim is currently the Director & Head-Research Center at Qurient Co., Ltd.
Previously, he worked as the Communications Director at Institut Pasteur Korea Research Foundation.
He holds a doctorate degree from The State University of New York.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
QURIENT CO., LTD.
0.66% | 19-12-2023 | 178 675 ( 0.66% ) | 546 524 $ | 31-05-2024 |
Actieve functies van Jae-Seung Kim
Bedrijven | Functie | Begin |
---|---|---|
QURIENT CO., LTD. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Jae-Seung Kim
Bedrijven | Functie | Einde |
---|---|---|
Institut Pasteur Korea Research Foundation
![]() Institut Pasteur Korea Research Foundation BiotechnologyHealth Technology Institut Pasteur Korea Research Foundation provides research and development for the treatment of infectious and chronic diseases. It develops a technology-based approach to therapeutic development through cellular models, high content screening and medicinal chemistry. The company was founded on December 29, 2003 and is headquartered in Seongnam, South Korea. | Investor Relations Contact | - |
Opleiding van Jae-Seung Kim
The State University of New York | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
QURIENT CO., LTD. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Institut Pasteur Korea Research Foundation
![]() Institut Pasteur Korea Research Foundation BiotechnologyHealth Technology Institut Pasteur Korea Research Foundation provides research and development for the treatment of infectious and chronic diseases. It develops a technology-based approach to therapeutic development through cellular models, high content screening and medicinal chemistry. The company was founded on December 29, 2003 and is headquartered in Seongnam, South Korea. | Health Technology |